unfixed Latanoprost and Timolol — Competitive Intelligence Brief

unfixed Latanoprost and Timolol (unfixed Latanoprost and Timolol) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Prostaglandin analogue and beta-adrenergic receptor blocker. Area: Ophthalmology.

phase 3 Prostaglandin analogue and beta-adrenergic receptor blocker Beta-adrenergic receptor Ophthalmology Small molecule

Target snapshot

unfixed Latanoprost and Timolol (unfixed Latanoprost and Timolol) — Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Latanoprost is a prostaglandin analogue that reduces intraocular pressure by increasing uveoscleral outflow, while Timolol is a beta-adrenergic receptor blocker that reduces intraocular pressure by decreasing aqueous humor production.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
unfixed Latanoprost and Timolol TARGET	unfixed Latanoprost and Timolol	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	phase 3	Prostaglandin analogue and beta-adrenergic receptor blocker	Beta-adrenergic receptor
ISOPROTERENOL	ISOPROTERENOL		marketed	Beta-adrenergic agonist	beta-adrenergic receptors	1956-01-01
Norepinephrine Bitartrate In 5% Dextrose	NOREPINEPHRINE	Pfizer	marketed	Catecholamine	alpha-adrenergic receptors, beta-adrenergic receptors	1950-01-01
Bupivicaine + epinephrine	Bupivicaine + epinephrine	Rush University Medical Center	marketed	Local anesthetic with vasopressor	Voltage-gated sodium channels; alpha and beta-adrenergic receptors
Intravenous amiodarone(2)	Intravenous amiodarone(2)	Instituto de Cardiología y Medicina Vascular Hospital Zambrano-Hellion Tec Salud	marketed	Class III antiarrhythmic agent	Potassium channels (hERG), sodium channels, beta-adrenergic receptors, calcium channels
dorzolamide/timolol	dorzolamide/timolol	CT Glaucoma Associates	marketed	Carbonic anhydrase inhibitor / Beta-adrenergic antagonist combination	Carbonic anhydrase II / Beta-adrenergic receptors (β1 and β2)
Empagliflozin + Carvedilol	Empagliflozin + Carvedilol	Post Graduate Institute of Medical Education and Research, Chandigarh	marketed	SGLT2 inhibitor + non-selective beta-blocker combination	SGLT2 and beta-adrenergic receptors (β1, β2, α1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Prostaglandin analogue and beta-adrenergic receptor blocker class)

1. Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · 1 drug in this class